Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-11-23
Based on 573 first isolates · SURG · Skin / wound infection · 2024-11-24 → 2025-11-23
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 55 % (51 %–59 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (12 %), Proteus mirabilis (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
55 %
46 %
n = 26
meropenem MEM
trend · Pseudomonas aeruginosa reserve
44 %
54 %
n = 26
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
43 %
31 %
n = 26
41 %
46 %
n = 26
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
40 %
42 %
n = 26
ceftriaxone CRO
trend · Escherichia coli
27 %
19 %
n = 26
25 %
19 %
n = 26
21 %
27 %
n = 26
12 %
19 %
n = 26
mecillinam MEC
not for this site
0 %
0 %
n = 26
trimethoprim TMP
not for this site
0 %
0 %
n = 26
nitrofurantoin NIT
not for this site
0 %
0 %
n = 26

Most likely organisms for this profile

Staphylococcus aureus
45 %
Pseudomonas aeruginosa
14 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
9 %
Citrobacter freundii
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.